Avaap Named Infor Alliance Partner of the Year Third Year in a Row
Aug 25, 2016 12:00 pm UTC| Business
EDISON, N.J., Aug. 25, 2016 -- Avaap, the largest Infor systems integrator, announced today it is the recipient of three 2016 Americas Partner Summit Awards. The three awards include Infor Alliance Partner of the Year,...
NanoString Technologies to Present at Two Upcoming Healthcare Conferences
Aug 25, 2016 12:00 pm UTC| Business
SEATTLE, Aug. 25, 2016 -- NanoString Technologies, Inc.(NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is...
Aug 25, 2016 12:00 pm UTC| Business
KFAR SABA, Israel, Aug. 25, 2016 -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that Dr. Shai Yarkoni,...
Smart Card Alliance and ASIS International Reach Agreement on Continuing Education Credits
Aug 25, 2016 12:00 pm UTC| Business
PRINCETON JUNCTION, N.J., Aug. 25, 2016 -- Individuals who pass the Smart Card Alliance’s Certified System Engineer ICAM PACS (CSEIP) exam may now be eligible to receive Continuing Education credits or Continuing...
Bioblast Pharma Reports Second Quarter 2016 Financial Results
Aug 25, 2016 12:00 pm UTC| Business
TEL AVIV, Israel, Aug. 25, 2016 -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the second quarter ended June 30, 2016. The...
Leading Financial Services Company selects Bridgeline’s iAPPS
Aug 25, 2016 12:00 pm UTC| Business
BURLINGTON, Mass., Aug. 25, 2016 -- Bridgeline Digital, Inc. (NASDAQ:BLIN) announced today that one of the nation’s top financial services companies selected iAPPS to power its insurance portal. “Though we serve...
Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial
Aug 25, 2016 12:00 pm UTC| Business
NORCROSS, Ga., Aug. 25, 2016 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announces interim results from an exploratory, open-label, Phase 2a clinical...